Figure 3
Figure 3. Differentiation and activation of CD45RO−/RA+ CD27+ HIV-specific CD8+ T cells in HAART-treated participants. (A) PBMCs were isolated from HAART-treated participants and labeled with HIV-multimer-PE; CCR7-FITC, CD28-FITC, or CD62L-FITC; CD45RO-ECD and CD8-PC5. Representative phenotypes gated on CD45RO−/RA+ CD8+ T cells. The majority of CD45RO−/RA+ HIV-specific CD8+ T cells did not express CCR7, CD28, or CD62L as opposed to global CD45RO−/RA+ HIV-multimer negative CD8+ T cells. (B) PBMCs were isolated from HAART-treated participants and stained with HIV-multimer-PE; CD38-FITC, HLA-DR-FITC, or Ki-67-FITC; CD45RO-ECD and CD8-PC5. Representative phenotypes gated on HIV-specific CD8+ T cells.

Differentiation and activation of CD45RO/RA+ CD27+ HIV-specific CD8+ T cells in HAART-treated participants. (A) PBMCs were isolated from HAART-treated participants and labeled with HIV-multimer-PE; CCR7-FITC, CD28-FITC, or CD62L-FITC; CD45RO-ECD and CD8-PC5. Representative phenotypes gated on CD45RO/RA+ CD8+ T cells. The majority of CD45RO/RA+ HIV-specific CD8+ T cells did not express CCR7, CD28, or CD62L as opposed to global CD45RO/RA+ HIV-multimer negative CD8+ T cells. (B) PBMCs were isolated from HAART-treated participants and stained with HIV-multimer-PE; CD38-FITC, HLA-DR-FITC, or Ki-67-FITC; CD45RO-ECD and CD8-PC5. Representative phenotypes gated on HIV-specific CD8+ T cells.

Close Modal

or Create an Account

Close Modal
Close Modal